Process Development and Scale-Up of the SOS1 Inhibitor MRTX0902
Open Access
- 22 May 2023
- journal article
- research article
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 27 (6) , 1061-1068
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- Mirati Therapeutics (MRTX0902)
This publication has 5 references indexed in Scilit:
- Development of Adagrasib’s Commercial Manufacturing RouteChemRxiv, 2022
- Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein–Protein InteractionJournal of Medicinal Chemistry, 2022
- Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of CancerJournal of Medicinal Chemistry, 2020
- Development of a Scalable Synthesis of Dipeptidyl Peptidase-4 Inhibitor ABT-279Organic Process Research & Development, 2009
- A LiCl‐Mediated Br/Mg Exchange Reaction for the Preparation of Functionalized Aryl‐ and Heteroarylmagnesium Compounds from Organic BromidesAngewandte Chemie International Edition, 2004